U.S. License Holder:
Dyax Corp.
Date of License:
August-23-2018
Last Update:
Sep-30-2024
FDA-Approved Indications
TAKHZYRO (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.